Mice injected with AAV-αSyn received 10 mg/kg/day KYP-2047
(n = 10) orHUP-55 (n = 10) and vehicle (n = 10) treatment in minipumps
4 weeks after the virus vector surgeries. The dose was based on our
earlier studies with AAV2-CBAαSyn virus vector experiment with
mice,47 (link),57 (link) αSyn transgenic mice,22 (link) and on brain pharmacokinetic study with KYP-2047.46 (link) The treatment lasted for 4 weeks. AAV-GFP-injected
mice receivedHUP-55 treatment 10 mg/kg/day. Osmotic
minipump (Alzet 1004, Durect; flow rate of 0.11 μL/h) implanted
in the abdominal cavity was used to provide chronic administration.
Priming doses dissolved in 5% Tween 80 in saline (i.p., 10 mg/kg)
were given on the first day of the treatment to ensure the immediate
onset of the drug effect.
(n = 10) or
4 weeks after the virus vector surgeries. The dose was based on our
earlier studies with AAV2-CBAαSyn virus vector experiment with
mice,47 (link),57 (link) αSyn transgenic mice,22 (link) and on brain pharmacokinetic study with KYP-2047.46 (link) The treatment lasted for 4 weeks. AAV-GFP-injected
mice received
minipump (Alzet 1004, Durect; flow rate of 0.11 μL/h) implanted
in the abdominal cavity was used to provide chronic administration.
Priming doses dissolved in 5% Tween 80 in saline (i.p., 10 mg/kg)
were given on the first day of the treatment to ensure the immediate
onset of the drug effect.
Free full text: Click here
